Discovering new blood-based signals for monitoring brain tumours in children
Dr Alina Pandele at the University of Nottingham hopes to find fragments cancer cell genetic code in the blood which can help doctors know when ependymoma grows back.
Developing new cancer treatment testing models for children with leukaemia
Dr Katrina Lappin aims to create a cost effective and more accurate acute myeloid leukaemia model to test treatments on.
Using an asthma medicine to harness the immune system and prevent childhood leukaemia from returning
Dr Sophie Kellaway at the University of Nottingham is investigating whether an asthma drug could help provide a new, targeted treatment for acute myeloid leukaemia.
Targeting a protein to treat acute myeloid leukaemia in children
Dr Karen Keeshan is researching to see if removing or blocking a specific protein involved in acute myeloid leukaemia can help make it easier to treat.
Studying immune cells to help develop new treatments for babies with leukaemia
Dr Samanta Mariani and her team want to understand more about the role immune cells play to help develop new ways to treat leukaemia in babies.
Creating innovative new treatments for childhood rhabdomyosarcoma by harnessing the body’s natural defence system
Dr Matthew Blunt aims to create and test immunotherapy treatments for rhabdomyosarcoma that are safer and more effective than chemotherapy.
Blocking the activity of an essential protein to treat T-cell acute lymphoblastic leukaemia
Dr Maarten Hoogenkamp will continue his work into blocking the EAAT1 protein, which is crucial for the growth of T-cell acute lymphoblastic leukaemia.
Developing a new drug for the treatment of ALT-positive cancers
Dr Jon Elkins and Dr Anna Rose at the University of Oxford hope to develop a new drug which will affect vital ALT-positive cancer cell processes.
Finding kinder drugs in genetically matched cell models for childhood leukaemia
Professor Alex Thompson and his team at the University of Nottingham aim to learn more about leukaemia to support the development of kinder treatments.